With all patients continuing dosing until 250 events occure, that in itself will mean the time line for final release of the results will be extended because they cannot start the evaluation and safety assesment until the patients have stopped dosing. So this means there will be 2400 plus assesments to be done and who will be doing these? Resverlogix doesn't have the staff to complete these in a timely manner. Allowing extended dosing has increased the cost of the trial as well as the length of the trial. I think we will be lucky to get final results by the end of the first half of 2019 especially if we don"t reach 250 events by March. 

Then there is the issue about the U.S. market listing. I just have a gut feeling there is more to the reverse split approval they received at the AGM then is mentioned. We all know if we get any type of positive result from this trial our share price will negate the need for this discussion, so why are they  going down this road? What do they know that we don't? How does any of this really fit into hiring Rothchild and at what expense. What agreement have they put together? Oh well just some rambling on a slow day. Jmho.